Conducted by researchers at NYU Langone, one of the nation’s premier academic medical centers, a new study has just been released on the positive effects of psilocybin on alcohol addiction.
Two doses of psilocybin were shown to reduce heavy drinking by 83% among heavy drinkers when combined with psychotherapy. The study also showed that eight months after their first dose, almost half (48%) of those who received psilocybin stopped drinking altogether (compared with 24% of the placebo group).
Results were published in JAMA psychiatry.
Watching the press conference, we heard from two trial participants. One was Jon Kostas, who shared his experience. Kostas was a longtime alcoholic who’d unsuccessfully tried many other treatments. He was considered treatment-resistant before signing up for the trial (Kostas’s session was back in 2015).:
“I was scared about trying psychedelics, but it felt like my only other option was death…and I stopped drinking right after my first psilocybin session”
“It worked like an antibiotic. I was sick. And it eliminated my cravings. I don’t consider myself an alcoholic anymore. And I haven’t taken another psychedelic session since the trial”
Of course, we must footnote this with the usual “these results require continued research and replication in larger sample sizes”. But 93 participants is a very respectable patient group and with the research being done at a reputable academic institution like the NYU Grossman School of Medicine, these results are another very valuable data point in the march towards treatment alternatives and regulatory approval (Awakn Life Science had similar results, 86% efficacy, in their Phase 2 trial for alcohol using ketamine)
See the full press release below.
Psychedelic Drug Therapy May Help Treat Alcohol Addiction
Two doses of psilocybin, a compound found in psychedelic mushrooms, reduces heavy drinking by 83% on average among heavy drinkers when combined with psychotherapy, a new study shows.
Led by researchers at NYU Grossman School of Medicine, the investigation involved 93 men and women with alcohol dependence. They were randomly assigned to receive either two doses of psilocybin or an antihistamine placebo. Neither the researchers nor the study participants knew which medication they received. Within an eight-month period from the start of their treatment, those who were given psilocybin reduced heavy drinking by 83% relative to their drinking before the study began. Meanwhile, those who had received antihistamine reduced their drinking by 51%.
Among the other key findings, the study showed that eight months after their first dose, almost half (48%) of those who received psilocybin stopped drinking altogether compared with 24% of the placebo group.
“Our findings strongly suggest that psilocybin therapy is a promising means of treating alcohol use disorder, a complex disease that has proven notoriously difficult to manage,” says study senior author and psychiatrist Michael Bogenschutz, MD, director of the NYU Langone Center for Psychedelic Medicine.
The U.S. Centers for Disease Control and Prevention reports that excessive alcohol use kills roughly 95,000 Americans every year, often due to binge drinking or liver disease. It is also linked to enormous economic and workplace losses, injury accidents, and impaired learning, memory, and mental health, says Bogenschutz, also a professor in the Department of Psychiatry at NYU Langone Health. Current methods to prevent excessive alcohol use and dependency include psychological counseling, supervised detoxification programs, and certain drug regimens that dampen cravings.
According to study investigators, previous research had already identified psilocybin treatment as an effective means of alleviating anxiety and depression in people with the most severe forms of cancer. And earlier research by Bogenschutz and others suggested that psilocybin could serve as a potential therapy for alcohol use disorder and other addictions.
The new study, publishing Aug. 24 in the journal
JAMA Psychiatry, is the first placebo-controlled trial to explore psilocybin as a treatment for excessive alcohol consumption, according to the study authors.
For the investigation, the research team recruited men and women who were diagnosed with alcohol dependence based on standard definitions and consumed on average seven drinks on days when they drank. Forty-eight patients received at least one dose and up to three doses of psilocybin, and 45 patients received the antihistamine placebo.
All received up to 12 psychotherapy sessions. These took place both before and after the drug treatments. Afterwards, the participants were asked to report the percentage of heavy drinking days they experienced during weeks 5 to 36 of the study. They also provided hair and fingernail samples to confirm that they had not been drinking. All participants were then offered a third session of psilocybin to ensure that those who previously received a placebo had the chance to be treated with the psychedelic drug.
“As research into psychedelic treatment grows, we find more possible applications for mental health conditions,” says Bogenschutz. “Beyond alcohol use disorder, this approach may prove useful in treating other addictions such as cigarette smoking and abuse of cocaine and opioids.”
Bogenschutz says the research team next plans to conduct a larger, multicenter trial under an FDA IND sponsored by B.More Inc.
He cautions that more work needs to be done to document psilocybin’s effects and to clarify appropriate dosing before the drug is ready for widespread clinical use. He notes that researchers have started such trials.
Psilocybin is a naturally occurring compound derived from fungi with mind-altering qualities similar to those of LSD and mescaline. Most study participants experience profound alterations in perception, emotions, and sense of self, often including experiences which are felt to be of great personal and spiritual significance. Because the drug raises blood pressure and heart rate and can cause incapacitating and sometimes overwhelming psychological effects, researchers caution that it should only be used in carefully controlled settings and in conjunction with psychological evaluation and preparation.
Funding for the study was provided by the Heffter Research Institute and individual donations from Carey and Claudia Turnbull, Dr. Efrem Nulman, Rodrigo Niño, and Cody Swift. Bogenschutz has received research funds from and served as a consultant to Mind Medicine, the Multidisciplinary Association for Psychedelic Studies, B. More, AJNA Labs, Beckley Psytech, Journey Colab, and Bright Minds Biosciences. None of these organizations were involved in funding the current study.
In addition to Bogenschutz, other NYU Langone researchers include Stephen Ross, MD; Tara Baron, MA; Eugene Laska, PhD; Sarah Mennenga, PhD; Kelley O’Donnell, MD, PhD; Samantha Podrebarac, MA, MSc; and John Rotrosen, MD. Other researchers were Snehal Bhatt, MD; Jeffrey Tonigan, PhD; and Lindsay Worth, LMHC, MPA, MA, at the University of New Mexico in Albuquerque. Additional investigators included Alyssa Forcehimes, PhD, at the Change Companies in Carson City, Nev.; and Lindsey Owens, MA, at the University of Alabama at Birmingham.
Media Inquiries:
Shira Polan
Phone: 212-404-4279
shira.polan@nyulangone.org